Humacyte (NASDAQ:HUMA) Announces Earnings Results

Humacyte (NASDAQ:HUMA) posted its quarterly earnings results on Monday. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09), Zacks reports.

Humacyte Stock Performance

Shares of HUMA stock opened at $2.48 on Monday. The stock has a market capitalization of $384.70 million, a PE ratio of -3.59 and a beta of 1.90. Humacyte has a 52-week low of $1.15 and a 52-week high of $8.24. The stock’s 50-day moving average price is $2.40 and its 200 day moving average price is $2.53. The company has a quick ratio of 3.28, a current ratio of 3.68 and a debt-to-equity ratio of 0.36.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Wall Street Zen upgraded Humacyte from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright started coverage on Humacyte in a research report on Wednesday, May 14th. They set a “buy” rating and a $4.00 target price on the stock. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Wednesday, July 23rd. Finally, Benchmark cut their target price on Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.71.

Hedge Funds Weigh In On Humacyte

A hedge fund recently raised its stake in Humacyte stock. Geode Capital Management LLC boosted its stake in Humacyte, Inc. (NASDAQ:HUMA) by 33.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,948,508 shares of the company’s stock after acquiring an additional 738,142 shares during the period. Geode Capital Management LLC owned 1.90% of Humacyte worth $6,163,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.